HIV-1-INFECTION

This early-phase trial is testing two experimental HIV vaccines in 52 healthy adults without HIV. The goal is to see if the vaccines are safe and can stimulate the immune system to produce broadly neutralizing antibodies, which are key to fighting many HIV strains. Participants r…

This early-stage trial is testing two experimental HIV vaccines, DV700P-RNA and DV701B1.1-RNA, for the first time in people. The study will enroll 45 healthy adults without HIV to check if the vaccines are safe and whether they trigger an immune response. Participants will receiv…

This early-stage trial tests two experimental HIV vaccines, UVAX-1107 and UVAX-1197, in 25 healthy adults without HIV. The goal is to check if the vaccines are safe and whether they trigger an immune response. Participants will receive injections and be followed for about a year.

This early-stage study is testing the safety and how the body handles a new combination HIV drug (B/F/TAF) in full-term newborns who were exposed to HIV at birth. The goal is to see if this drug can be used to prevent the babies from getting infected. The study involves 16 infant…

This study tests whether switching to a new 2-drug combination pill (bictegravir/lenacapavir) is as safe and effective as staying on the standard 3-drug pill (Biktarvy) for people with HIV-1 whose virus is already suppressed. About 577 participants who have been on Biktarvy for a…

This study planned to test a blend of plant extracts and vitamin C, called Ahah, in people with HIV/AIDS. The goal was to see if it could protect and increase CD4+ T cells and B cells. However, the trial was withdrawn before enrolling any participants, so no results are available…

This study tests a new combination of two HIV drugs, bictegravir and lenacapavir, in children and adolescents aged 2 to 17 with HIV-1. The goal is to see if this once-daily pill is safe and works well enough to replace more complex daily medication routines. About 75 participants…

This early-stage study tests a single dose of a new long-acting antibody in 20 people with HIV who are not on regular medication. The goal is to see if the antibody is safe and can lower the amount of virus in the blood. Results will help design future studies for both HIV treatm…

This phase 3 trial tests whether a once-weekly pill (islatravir/lenacapavir) can keep HIV under control as well as daily standard care. About 600 people with HIV who already have undetectable virus levels will switch to the weekly pill or stay on their current daily regimen. The …

This study tests whether a combination of two antibodies (TMB-365 and TMB-380) given as an infusion every 8 weeks can keep HIV under control in people who are already suppressed on daily oral medication. About 88 adults with HIV will either switch to the antibody infusions or sta…

This study tests whether pomalidomide, a drug currently used for multiple myeloma, can help control HIV when people temporarily stop their standard antiretroviral therapy (ART). Thirty-two adults with well-controlled HIV will receive either pomalidomide or a placebo alongside low…

This study tests whether people with HIV who are already well-controlled on a daily pill (B/F/TAF) can safely switch to a once-weekly tablet (islatravir/lenacapavir). About 600 participants will take either the weekly pill or continue their daily regimen for 48 weeks. The goal is…

This study tests whether a combination of two lab-made antibodies and an antiviral drug called lenacapavir, given every 6 months, can keep HIV under control in adults whose virus is already suppressed by daily pills. About 83 participants will either switch to the new long-acting…

This study tests whether a new once-weekly oral combination of two experimental drugs, lepetegravir and lenacapavir pacfosacil, can keep HIV under control as well as the daily pill Biktarvy. About 675 adults with already-suppressed HIV will take either the weekly combo or continu…

This study looks at whether older adults (60+) living with HIV in Kenya can safely switch from their current three-drug pill to a simpler two-drug pill called DTG/3TC. About 240 participants who are already stable on treatment will be followed for 96 weeks. The main goal is to se…

This study tests whether two lab-made antibodies can safely control HIV in people who stop their regular antiretroviral therapy for a short time. Thirty-two adults in Sub-Saharan Africa who are currently on HIV treatment will receive either the antibodies or a placebo. The goal i…

This study is testing the HIV medication Biktarvy (a combination of three drugs) in adolescents and children who have HIV-1. The goal is to see how the drug works in younger bodies, confirm the right dose, and check for side effects. About 177 participants will take the pill once…

This study tests a new medicine called lenacapavir in people with HIV whose current drugs are no longer working due to multidrug resistance. The drug is given as a pill and an injection, and is added to their failing regimen for 14 days before switching to an optimized background…

This early-phase trial tests whether a combination of two experimental vaccines, an immune booster, and two powerful antibodies can help people with HIV control the virus after stopping their daily antiretroviral therapy. Eleven participants will receive the regimen while on ART,…

This study tests whether giving people with HIV same-day results from a simple urine test and a viral load test can help them stick to their medication and keep the virus under control. About 539 people starting HIV treatment in South Africa will take part. The goal is to see if …

This study tests if a once-weekly combination of two oral drugs, islatravir and lenacapavir, can keep HIV under control in people whose virus is already suppressed. 142 participants switched from their daily HIV pill to this weekly regimen. The main goal is to see if the virus st…

This study is checking the long-term safety of a once-daily pill containing two HIV drugs (doravirine and islatravir) in 2,000 adults with HIV-1 who already took it in earlier studies. Participants will take the pill for up to 192 weeks. The goal is to see how many people have se…

This study tests whether switching to a once-daily pill containing doravirine and islatravir (DOR/ISL) works as well as staying on current HIV medications for people whose virus is already undetectable. About 550 adults with HIV-1 who have been on stable therapy for at least 3 mo…

This study tests if people with HIV whose virus is already well-controlled on a standard three-drug pill (BIC/FTC/TAF) can safely switch to a new two-drug pill (DOR/ISL) taken once daily. About 514 adults with suppressed HIV will be randomly assigned to either stay on their curre…

This study tests a new once-daily pill (doravirine/islatravir) for adults with HIV who have never taken HIV medication before. About 537 participants will receive either the new pill or a standard combination pill to see how well they control the virus and if they cause side effe…

This study tests whether people with HIV who are already virally suppressed on complex treatment can safely switch to a simpler two-drug combination of bictegravir and lenacapavir. About 689 participants will be randomly assigned to either switch to the new drugs or stay on their…

This study follows 11 people who previously received a gene therapy called Cal-1 for HIV. The goal is to watch for any delayed side effects over many years. Researchers will also check whether the modified cells are still present and active in the blood. It is a safety-only study…

This study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…

This study looks at how to best help HIV clinics in Vietnam offer a short alcohol counseling program to patients who drink heavily. The goal is to reduce risky drinking and lower the chance of spreading HIV. Over 3,200 people living with HIV and clinic staff are taking part to se…

This study tests whether a home-based walking program can improve blood sugar, cholesterol, and body measurements in people living with HIV who also have metabolic syndrome. Fifty participants will gradually increase their walking over six months. The main goal is to see if the p…

This study looks at how HIV infection and aging impact the body's response to the Prevnar 13 vaccine, which protects against pneumococcal bacteria. Researchers will measure antibody levels in the lungs, nasal passages, and blood of participants aged 21-45 or 55-75, comparing thos…

This pilot study aimed to see if a home viral load test (TASSO device) is accurate and easy to use for people starting HIV treatment or trying to lower a high viral load. Participants would have collected samples at home and in the clinic. However, the study was withdrawn before …

This study looks at 40 people with HIV to see if a common drug, tenofovir, causes more immune system activation and helps the virus hide better in the body. Participants are already on stable HIV treatment and will provide blood and gut samples. The goal is to find ways to reduce…

This study involves 48 adults with HIV who have had undetectable virus levels for at least 2 years while on antiretroviral therapy. Researchers are measuring two specific markers (CD32a and X) on immune cells to see if they relate to the amount of hidden HIV DNA in the body. The …